Drug Profile


Alternative Names: Acofide; Acotiamide hydrochloride hydrate; YM 443; Z-338

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zeria
  • Developer Astellas Pharma; Zeria
  • Class Benzamides; Gastrokinetics; Small molecules; Thiazoles
  • Mechanism of Action Acetylcholine stimulants; Acetylcholinesterase inhibitors; Muscarinic M1 receptor antagonists; Muscarinic M2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-ulcer dyspepsia
  • Phase II Helicobacter infections

Most Recent Events

  • 01 Apr 2017 Zeria Pharmaceutical completes a phase III trial in Non-ulcer dyspepsia in Belgium, Bulgaria, Latvia, Lithuania, Romania, Russia, Slovakia, Sweden, Ukraine, United Kingdom (NCT01973790)
  • 13 Feb 2017 Acotiamide is still in phase-II development for Non-ulcer dyspepsia in USA (PO) (Zeria pipeline, February 2017)
  • 01 Sep 2016 Phase-II clinical trials in Helicobacter infections in Japan (PO) (UMIN000023886)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top